01—Abstract
Summary
Summary of the 10-K filed February 14, 2017. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported total revenue of $1,681,432 thousanda ($1.68 billion) for fiscal 2016, up from $1,363,302 thousand in 2015, with revenue growth of 23.3% driven largely by the WIL Research acquisition.
Operating income rose to $237,419 thousandb from $206,449 thousand, and income from continuing operations was $156,086 thousand, or $3.22 per diluted share. The company describes itself as a full-service, early-stage contract research organization with three segments: Research Models and Services (29.4% of 2016 revenue), Discovery and Safety Assessment (49.8%), and Manufacturing Support (20.9%). The year was dominated by acquisitions.
Charles River acquired WIL Research for $604.8 millionc in April 2016, along with Blue Stream and Agilux, and it reported total debt of $1,212.7 million at year end, up from $836.0 million a year earlier. Net cash provided by operating activities was $300,375 thousand. The company also disclosed a subsequent event: on February 10, 2017 it divested its CDMO business to Quotient Clinical Ltd. for $75.0 million in cash, and on February 6, 2017 it settled the IDEXX patent litigation.
The filing notes that demand for safety assessment services improved in 2016, particularly from biotechnology clients, and that demand from large biopharmaceutical clients for early discovery services fluctuated. Management highlights risks including outsourcing trends, government and R&D budget fluctuations, contamination in animal populations, fixed-price contracts, international operations, and a 100-basis-point rise in interest rates that would increase annual pre-tax interest expense by approximately $12.1 milliond. The company paid no cash dividends and had $69.7 million remaining under its stock repurchase authorization at year end.
02—Key points
Key Highlights
- Total revenue of $1,681,432 thousand in fiscal 2016, up 23.3% from $1,363,302 thousand in fiscal 2015.
- Operating income of $237,419 thousand, up from $206,449 thousand; income from continuing operations of $156,086 thousand, or $3.22 per diluted share.
- DSA segment revenue of $836.6 million (49.8% of total), up 36.7%, with WIL Research contributing $163.5 million of revenue growth in Safety Assessment.
- WIL Research acquired in April 2016 for $604.8 million; Blue Stream ($11.7 million) and Agilux ($64.9 million) also acquired in 2016.
- Total debt of $1.2 billion at December 31, 2016, up from $836.0 million; the company was compliant with all credit facility covenants.
- Divested the CDMO business to Quotient Clinical Ltd. on February 10, 2017 for $75.0 million in cash.
- Net cash provided by operating activities of $300,375 thousand in 2016, compared with $288,234 thousand in 2015.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2016, Charles River Laboratories International kept $0.09.
- Revenue$1.68B100.0%
- Cost of revenue−$277.0M16.5%
- Gross profit$1.40B83.5%
- Operating costs−$1.17B69.4%
- Operating income$237.6M14.1%
- Interest, other & tax−$82.8M4.9%
- Net income$154.8M9.2%
Where FY2016 revenue went
$1.68B- Other operating costs: $802.1M, 48% of revenue
- SG&A: $364.7M, 22% of revenue
- Cost of revenue: $277.0M, 16% of revenue
- Net income: $154.8M, 9.2% of revenue
- Interest, other & tax: $82.8M, 4.9% of revenue
Kept 9.2% as net incomeNet income $154.8M · 9.2%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2016filed February 14, 2017Financial Statements
FY2016 against FY2015
| Line item | FY2016FY2015 | Change |
|---|---|---|
| Revenue | $1.68B$1.36B | +23.3% |
| Cost of Revenue | $277.03M$263.98M | +4.9% |
| Gross Profit | $1.40B$1.10B | +27.8% |
| SG&A Expenses | $364.71M$300.41M | +21.4% |
| Operating Income | $237.55M$206.45M | +15.1% |
| Interest Expense | $27.71M$15.07M | +83.8% |
| Net Income | $154.76M$149.31M | +3.7% |
| EPS (Basic) | $3.29$3.21 | +2.5% |
| EPS (Diluted) | $3.23$3.13 | +3.2% |
| Shares Outstanding (Basic) | 47.01M46.50M | +1.1% |
| Shares Outstanding (Diluted) | 47.96M47.63M | +0.7% |
05—Questions
Frequently Asked Questions
How did Charles River's revenue and profitability change in fiscal 2016?
Total revenue rose to $1,681,432 thousand from $1,363,302 thousand, an increase of 23.3%, with a negative foreign currency effect of $20.0 million. Operating income increased to $237,419 thousand from $206,449 thousand, and income from continuing operations was $156,086 thousand, compared with $152,037 thousand in 2015.
What drove growth in the Discovery and Safety Assessment segment?
DSA revenue increased $224.4 million to $836.6 million, primarily due to the WIL Research acquisition, which contributed $163.5 million to revenue growth, along with increased study volume, service mix and pricing in the legacy Safety Assessment business. Early Discovery revenue declined due primarily to softer demand from global clients.
How much debt does Charles River carry and what are the key terms?
As of December 31, 2016, the company had $1.2 billion of debt, with total debt of $1,212.6 million under its $1.65 billion credit facility, including $633.8 million of term loans and $578.8 million drawn on the revolving facility. The facility matures March 30, 2021, and the company was in compliance with all covenants. A 100-basis-point increase in interest rates would raise annual pre-tax interest expense by approximately $12.1 million.
Are there any material legal matters or subsequent events investors should know about?
On February 6, 2017, the company settled the IDEXX patent infringement litigation, with IDEXX withdrawing its complaint and the company withdrawing its inter partes review. The company also recorded an estimated $1.8 million liability related to inaccurate billing on certain government contracts. Following the year end, on February 10, 2017, it completed the sale of its CDMO business for $75.0 million.
Does Charles River pay dividends or repurchase shares?
The company has not declared or paid cash dividends in the past two years and does not intend to pay them in the foreseeable future. It made no repurchases under its stock repurchase program during fiscal 2016, leaving $69.7 million remaining on the $1,150.0 million aggregate authorization.
06—Continue